In an earlier study, we also reported another truncating CHEK2 mutation, (ins1368A), to be associated with resistance to anthracycline therapy in a breast cancer patient [16]; thus, all these three mutations (R95*, Y390C and ins1368A) seem associated with defect DNA damage signaling leading to drug resistance. Here, CHEK2 is linked to breast carcinoma.